Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform on October 16, 2018 in New York City.

Arrowhead Pharmaceuticals to Host R&D Day on Emerging Pipeline of RNAi Therapeutics

Pasadena. CA | Posted on September 25th, 2018

The R&D Day will feature presentations by Ira Goldberg, M.D. (NYU Langone Medical Center) who will discuss the current treatment landscape and unmet medical need for patients with dyslipidemia and hypertriglyceridemia.

Arrowhead's management team will provide an overview of the company’s pipeline of RNAi-based therapeutics. Discussion topics will include:

ARO-APOC3 for patients with hypertriglyceridemia. A CTA filing is planned by the end of 2018.
ARO-ANG3 for patients with dyslipidemia. A CTA filing is planned by the end of 2018.
ARO-ENaC for patients with cystic fibrosis. A CTA filing is planned in 2019.
ARO-HIF2 for patients with renal cell carcinoma. A CTA filing is planned in 2019.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. To reserve a seat, please click here to register.

A live and archived webcast of the event, with slides, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Research Reveals Exotic Quantum States in Double-Layer Graphene: Findings shed new light on the nature of electron interactions in quantum systems and establish a potential new platform for future quantum computers June 26th, 2019

Researchers unveil how soft materials react to deformation at molecular level June 24th, 2019

Nanometrics and Rudolph Announce Merger Agreement to Create a Premier Semiconductor Process Control Company June 24th, 2019

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) June 22nd, 2019

Possible Futures

Research Reveals Exotic Quantum States in Double-Layer Graphene: Findings shed new light on the nature of electron interactions in quantum systems and establish a potential new platform for future quantum computers June 26th, 2019

Researchers unveil how soft materials react to deformation at molecular level June 24th, 2019

Nanometrics and Rudolph Announce Merger Agreement to Create a Premier Semiconductor Process Control Company June 24th, 2019

Researchers report new understanding of thermoelectric materials: Discovery leads to promising new materials for converting waste heat to power June 21st, 2019

Nanomedicine

Nanometrics and Rudolph Announce Merger Agreement to Create a Premier Semiconductor Process Control Company June 24th, 2019

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) June 22nd, 2019

'Nanoemulsion' gels offer new way to deliver drugs through the skin: Novel materials made with FDA-approved components could deliver large payloads of active ingredients June 21st, 2019

Millions with neurological diseases could find new option in implantable neurostimulation devices June 21st, 2019

Announcements

Research Reveals Exotic Quantum States in Double-Layer Graphene: Findings shed new light on the nature of electron interactions in quantum systems and establish a potential new platform for future quantum computers June 26th, 2019

Researchers unveil how soft materials react to deformation at molecular level June 24th, 2019

Nanometrics and Rudolph Announce Merger Agreement to Create a Premier Semiconductor Process Control Company June 24th, 2019

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) June 22nd, 2019

Events/Classes

Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences June 2nd, 2019

ACS selects Naomi Halas to represent Americas at ChinaNano: Rice U. pioneer wins 2019 ACS Nano Lectureship Award for the Americas May 29th, 2019

CEA-Leti Develops CMOS Process for High-Performance MicroLEDs That Could Overcome Display-Size Obstacles: New Concept Creates All-in-One RGB MicroLEDs, Eliminates Several Transfer Steps to Receiving Substrate & Boosts Performance May 16th, 2019

Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences May 3rd, 2019

Nanobiotechnology

Nanometrics and Rudolph Announce Merger Agreement to Create a Premier Semiconductor Process Control Company June 24th, 2019

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) June 22nd, 2019

'Nanoemulsion' gels offer new way to deliver drugs through the skin: Novel materials made with FDA-approved components could deliver large payloads of active ingredients June 21st, 2019

Millions with neurological diseases could find new option in implantable neurostimulation devices June 21st, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project